{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:33:52Z","timestamp":1789760032869,"version":"4.0.1"},"reference-count":196,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/rheumatology\/key002","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T15:09:58Z","timestamp":1516979398000},"source":"Crossref","is-referenced-by-count":60,"title":["Gout: state of the art after a decade of developments"],"prefix":"10.1093","author":[{"given":"Tristan","family":"Pascart","sequence":"first","affiliation":[{"name":"EA 4490, Lille University, Lille, France"},{"name":"Service de Rhumatologie, H\u00f4pital Saint-Philibert, Lomme, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[{"name":"UFR de M\u00e9decine, University of Paris Diderot, USPC, France"},{"name":"INSERM, UMR 1132 Bioscar (Centre Viggo Petersen), France"},{"name":"Service de Rhumatologie (Centre Viggo Petersen), P\u00f4le Appareil Locomoteur, H\u00f4pital Lariboisi\u00e8re (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"key\n\t\t\t\t20180314010236_key002-B1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180314010236_key002-B2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180314010236_key002-B3","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180314010236_key002-B4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B5","first-page":"ii2","article-title":"New insights into the epidemiology of gout","volume":"48 (Suppl 2)","author":"Doherty","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/acr.22896","article-title":"Survey definitions of gout for epidemiological studies: comparison with crystal identification as the gold standard","volume":"68","author":"Dalbeth","year":"2016","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1136\/annrheumdis-2013-204976","article-title":"Identification of patients with gout: elaboration of a questionnaire for epidemiological studies","volume":"74","author":"Richette","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","article-title":"Incidence and prevalence of gout in Western Sweden","volume":"18","author":"Dehlin","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/acr.22660","article-title":"Prevalence of gout in the adult population of France","volume":"68","author":"Bardin","year":"2016","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","article-title":"Epidemiology of gout and hyperuricaemia in Italy during the years 2005\u20132009: a nationwide population-based study","volume":"72","author":"Trifir\u00f2","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.semarthrit.2016.08.006","article-title":"The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012","volume":"46","author":"Rai","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B14","first-page":"1382","article-title":"Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease","volume":"25","author":"Chaiamnuay","year":"1998","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10067-013-2183-9","article-title":"Factors associated with gout in South Koreans: analysis using the National Health Insurance Corporation and the National Health Screening Exam databases","volume":"32","author":"Lee","year":"2013","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B18","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: what should we target?","volume":"10","author":"Richette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B19","doi-asserted-by":"crossref","first-page":"e0134088","DOI":"10.1371\/journal.pone.0134088","article-title":"Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180314010236_key002-B20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","article-title":"Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink","volume":"74","author":"Clarson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.22954","article-title":"The obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy","volume":"69","author":"Nguyen","year":"2017","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","article-title":"Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study","volume":"30","author":"Jing","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180314010236_key002-B27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2011.12.006","article-title":"GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n = 1003)","volume":"79","author":"Liot\u00e9","year":"2012","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jbspin.2015.10.006","article-title":"GOSPEL 2\u2014Colchicine for the treatment of gout flares in France\u2014a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age","volume":"83","author":"Pascart","year":"2016","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.rhu.0000164822.98163.22","article-title":"Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity","volume":"11","author":"Perez-Ruiz","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","article-title":"Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis","volume":"16","author":"Kanji","year":"2015","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t20180314010236_key002-B31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jbspin.2015.10.008","article-title":"Gout characteristics associate with depression, but not anxiety, in primary care: baseline findings from a prospective cohort study","volume":"83","author":"Prior","year":"2016","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B32","doi-asserted-by":"crossref","first-page":"e2401","DOI":"10.1097\/MD.0000000000002401","article-title":"High risk of depressive disorders in patients with gout: a nationwide population-based cohort study","volume":"94","author":"Changchien","year":"2015","journal-title":"Medicine"},{"key":"key\n\t\t\t\t20180314010236_key002-B33","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/annrheumdis-2015-208161","article-title":"Risk of incident atrial fibrillation in gout: a cohort study","volume":"75","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/kev418","article-title":"Impact of gout on the risk of atrial fibrillation","volume":"55","author":"Kuo","year":"2016","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/annrheumdis-2014-206917","article-title":"Gout and the risk of Alzheimer\u2019s disease: a population-based, BMI-matched cohort study","volume":"75","author":"Lu","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12883-015-0273-9","article-title":"Clinical associations between gout and multiple sclerosis, Parkinson\u2019s disease and motor neuron disease: record-linkage studies","volume":"15","author":"Pakpoor","year":"2015","journal-title":"BMC Neurol"},{"key":"key\n\t\t\t\t20180314010236_key002-B37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.amjmed.2015.11.003","article-title":"Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study","volume":"129","author":"Larsen","year":"2016","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B38","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/annrheumdis-2014-205269","article-title":"Allopurinol initiation and all-cause mortality in the general population","volume":"74","author":"Dubreuil","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B39","doi-asserted-by":"crossref","first-page":"e0146172","DOI":"10.1371\/journal.pone.0146172","article-title":"Impact of urate level on cardiovascular risk in allopurinol treated patients. A nested case\u2013control study","volume":"11","author":"S\u00f8ltoft Larsen","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180314010236_key002-B40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13075-015-0609-2","article-title":"An update on the genetic architecture of hyperuricemia and gout","volume":"17","author":"Merriman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.rdc.2014.01.009","article-title":"The genetic basis of gout","volume":"40","author":"Merriman","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t20180314010236_key002-B42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","article-title":"Genome-wide association analyses identify 18 new loci associated with serum urate concentrations","volume":"45","author":"K\u00f6ttgen","year":"2013","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180314010236_key002-B43","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/srep03755","article-title":"ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload","volume":"4","author":"Matsuo","year":"2014","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180314010236_key002-B44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11926-014-0492-x","article-title":"The gouty tophus: a review","volume":"17","author":"Chhana","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"key\n\t\t\t\t20180314010236_key002-B46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","article-title":"Hyperuricemia starts at 360 micromoles (6 mg\/dL)","volume":"82","author":"Bardin","year":"2015","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B47","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/annrheumdis-2014-206191","article-title":"Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes","volume":"75","author":"Matsuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B48","doi-asserted-by":"crossref","first-page":"20602","DOI":"10.1038\/srep20602","article-title":"Intestinal microbiota distinguish gout patients from healthy humans","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180314010236_key002-B49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"key\n\t\t\t\t20180314010236_key002-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2012.08.012","article-title":"Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts","volume":"80","author":"Pascual","year":"2013","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B51","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/ard.2006.063768","article-title":"Are joints affected by gout also affected by osteoarthritis?","volume":"66","author":"Roddy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B52","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1\u03b2 production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B53","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar3898","article-title":"Enhanced interleukin-1\u03b2 production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals","volume":"14","author":"Mylona","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/icb.2009.98","article-title":"Crystal-induced neutrophil activation","volume":"88","author":"Popa-Nita","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"key\n\t\t\t\t20180314010236_key002-B55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1074\/jbc.M110.139048","article-title":"Sodium overload and water influx activate the NALP3 inflammasome","volume":"286","author":"Schorn","year":"2011","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180314010236_key002-B56","first-page":"19","article-title":"Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis","volume":"19","author":"Cronstein","year":"2013","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B57","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/art.38747","article-title":"Contribution of mast cell-derived interleukin-1\u03b2 to uric acid crystal-induced acute arthritis in mice","volume":"66","author":"Reber","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B58","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/art.10326","article-title":"Monosodium urate monohydrate crystal\u2013induced inflammation in vivo: quantitative histomorphometric analysis of cellular events","volume":"46","author":"Schiltz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-016-1012-3","article-title":"Monosodium urate crystals induce oxidative stress in human synoviocytes","volume":"18","author":"Zamudio-Cuevas","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B60","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.1780390718","article-title":"Inhibition and prevention of monosodium urate monohydrate crystal\u2013induced acute inflammation in vivo by transforming growth factor \u03b21","volume":"39","author":"Liot\u00e9","year":"1996","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1189\/jlb.3A1015-453RRR","article-title":"Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice","volume":"101","author":"Vieira","year":"2017","journal-title":"J Leukoc Biol"},{"key":"key\n\t\t\t\t20180314010236_key002-B62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2014-206074","article-title":"AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages","volume":"75","author":"Wang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B63","doi-asserted-by":"crossref","first-page":"e000046","DOI":"10.1136\/rmdopen-2015-000046","article-title":"Why does the gout attack stop? A roadmap for the immune pathogenesis of gout","volume":"1","author":"Schett","year":"2015","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t20180314010236_key002-B64","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/annrheumdis-2014-205304","article-title":"Hyperuricaemia and gout: time for a new staging system?","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B65","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/15257770.2015.1124999","article-title":"Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout","volume":"35","author":"Puig","year":"2016","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key\n\t\t\t\t20180314010236_key002-B66","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/B978-1-4377-2864-4.10016-8","volume-title":"Gout & other crystal arthropathies","author":"Liot\u00e9","year":"2012"},{"key":"key\n\t\t\t\t20180314010236_key002-B67","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jbspin.2014.10.020","article-title":"The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions","volume":"82","author":"Kienhorst","year":"2015","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/annrheumdis-2014-206364","article-title":"Performance of classification criteria for gout in early and established disease","volume":"75","author":"Taylor","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B69","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archinternmed.2010.196","article-title":"A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis","volume":"170","author":"Janssens","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B70","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/rheumatology\/keu378","article-title":"The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study","volume":"54","author":"Kienhorst","year":"2015","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B71","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B72","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B73","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jbspin.2013.12.001","article-title":"Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients","volume":"81","author":"Kienhorst","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B74","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2214\/ajr.134.4.781","article-title":"A radiologic reevaluation of gout: a study of 2,000 patients","volume":"134","author":"Bloch","year":"1980","journal-title":"Am J Roentgenol"},{"key":"key\n\t\t\t\t20180314010236_key002-B75","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00330-007-0802-z","article-title":"Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray","volume":"18","author":"Rettenbacher","year":"2008","journal-title":"Eur Radiol"},{"key":"key\n\t\t\t\t20180314010236_key002-B76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00361124","article-title":"Gouty arthritis: a prospective radiographic evaluation of sixty patients","volume":"11","author":"Barthelemy","year":"1984","journal-title":"Skeletal Radiol"},{"key":"key\n\t\t\t\t20180314010236_key002-B77","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.22891","article-title":"Validation of a radiographic damage index in chronic gout","volume":"57","author":"Dalbeth","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B78","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1136\/annrheumdis-2015-208937","article-title":"Factors associated with change in radiographic damage scores in gout: a prospective observational study","volume":"75","author":"Eason","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B79","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1186\/ar3913","article-title":"Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography","volume":"14","author":"Dalbeth","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B80","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2013-205036","article-title":"Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ard.61.1.52","article-title":"Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography","volume":"61","author":"Gerster","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B82","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/rheumatology\/kep278","article-title":"An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs","volume":"48","author":"Carter","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B83","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00256-014-1869-7","article-title":"Exploring cartilage damage in gout using 3-T MRI: distribution and associations with joint inflammation and tophus deposition","volume":"43","author":"Popovich","year":"2014","journal-title":"Skeletal Radiol"},{"key":"key\n\t\t\t\t20180314010236_key002-B84","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/annrheumdis-2014-205431","article-title":"Imaging modalities for the classification of gout: systematic literature review and meta-analysis","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B85","first-page":"499","article-title":"Ultrasonography in gout: a case\u2013control study","volume":"30","author":"Ottaviani","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B86","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/rheumatology\/kev112","article-title":"International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise","volume":"54","author":"Gutierrez","year":"2015","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B87","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2013-203487","article-title":"Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?","volume":"73","author":"Naredo","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B88","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/rheumatology\/kem058","article-title":"Diagnosis of gout by ultrasound","volume":"46","author":"Thiele","year":"2007","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B89","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-015-0701-7","article-title":"A prospective evaluation of ultrasound as a diagnostic tool in acute microcrystalline arthritis","volume":"17","author":"Zufferey","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B90","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3899\/jrheum.150366","article-title":"Assessing elementary lesions in gout by ultrasound: results of an OMERACT patient-based agreement and reliability exercise","volume":"42","author":"Terslev","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B91","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.ultrasmedbio.2016.01.014","article-title":"Sonographic findings in gouty arthritis: diagnostic value and association with disease duration","volume":"43","author":"Elsaman","year":"2016","journal-title":"Ultrasound Med Biol"},{"key":"key\n\t\t\t\t20180314010236_key002-B92","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s10067-016-3309-7","article-title":"Tendon involvement in patients with gout: an ultrasound study of prevalence","volume":"35","author":"Ventura-R\u00edos","year":"2016","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B93","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jbspin.2014.03.011","article-title":"Ultrasound in gout: a useful tool for following urate-lowering therapy","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B94","first-page":"1888","article-title":"Ultrasonographic measurement of tophi as an outcome measure for chronic gout","volume":"34","author":"Perez-Ruiz","year":"2007","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B95","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3899\/jrheum.141294","article-title":"Ultrasound as an outcome measure in gout. A validation process by the OMERACT Ultrasound Working Group","volume":"42","author":"Terslev","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B96","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/acr.23082","article-title":"Ultrasound features of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: comparison with normouricaemic individuals","volume":"69","author":"Stewart","year":"2017","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B97","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/ard.2008.099713","article-title":"Dual energy computed tomography in tophaceous gout","volume":"68","author":"Choi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B98","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2012-202786","article-title":"Tendon involvement in the feet of patients with gout: a dual-energy CT study","volume":"72","author":"Dalbeth","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B99","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1007\/s00330-016-4237-2","article-title":"Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT","volume":"26","author":"Finkenstaedt","year":"2016","journal-title":"Eur Radiol"},{"key":"key\n\t\t\t\t20180314010236_key002-B100","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.clinimag.2014.12.015","article-title":"Clinical utility of dual-energy CT for gout diagnosis","volume":"39","author":"Hu","year":"2015","journal-title":"Clin Imaging"},{"key":"key\n\t\t\t\t20180314010236_key002-B101","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.acra.2015.10.019","article-title":"Dual-energy CT in patients with suspected gouty arthritis: effects on treatment regimen and clinical outcome","volume":"23","author":"Metzger","year":"2016","journal-title":"Acad Radiol"},{"key":"key\n\t\t\t\t20180314010236_key002-B102","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/annrheumdis-2013-205095","article-title":"Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study","volume":"74","author":"Bongartz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B103","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/annrheumdis-2011-200976","article-title":"Dual energy CT in gout: a prospective validation study","volume":"71","author":"Choi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B104","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/annrheumdis-2013-204273","article-title":"Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B105","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","article-title":"Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B106","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.acra.2015.08.010","article-title":"Comparison between dual-energy computed tomography and ultrasound in the diagnosis of gout of various joints","volume":"22","author":"Zhu","year":"2015","journal-title":"Acad Radiol"},{"key":"key\n\t\t\t\t20180314010236_key002-B107","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13075-017-1381-2","article-title":"Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study","volume":"19","author":"Pascart","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/acr.22754","article-title":"Development of a dual energy computed tomography scoring system for measurement of urate deposition in gout","volume":"68","author":"Bayat","year":"2015","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B109","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/rmdopen-2015-000075","article-title":"Tophus resolution with pegloticase: a prospective dual-energy CT study","volume":"1","author":"Araujo","year":"2015","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t20180314010236_key002-B110","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar4343","article-title":"Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study","volume":"15","author":"Rajan","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-016-1105-z","article-title":"Urate crystal deposition and bone erosion in gout: \u2018inside-out\u2019 or \u2018outside-in\u2019? A dual-energy computed tomography study","volume":"18","author":"Towiwat","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B112","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/ket341","article-title":"Dual-energy computed tomography compared with ultrasound in the diagnosis of gout","volume":"53","author":"Gruber","year":"2014","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B113","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00296-014-2979-1","article-title":"Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout","volume":"34","author":"Huppertz","year":"2014","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t20180314010236_key002-B114","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B115","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B116","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180314010236_key002-B117","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/M14-2070","article-title":"Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial","volume":"164","author":"Rainer","year":"2016","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B118","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B119","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3899\/jrheum.110916","article-title":"Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial","volume":"39","author":"Schumacher","year":"2012","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B120","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180314010236_key002-B121","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kem090","article-title":"Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout","volume":"46","author":"Willburger","year":"2007","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B122","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180314010236_key002-B123","first-page":"100","article-title":"Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case\u2013time\u2013control study","volume":"3","author":"Sondergaard","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180314010236_key002-B124","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbspin.2012.09.009","article-title":"ACTH as first line treatment for acute gout in 181 hospitalized patients","volume":"80","author":"Daoussis","year":"2013","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B126","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B127","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B128","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B130","first-page":"1061","article-title":"Adverse drug reactions and drug\u2013drug interactions with over-the-counter NSAIDs","volume":"11","author":"Moore","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"key\n\t\t\t\t20180314010236_key002-B131","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B132","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180314010236_key002-B133","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1345\/aph.1E593","article-title":"Acute myopathy in a patient with concomitant use of pravastatin and colchicine","volume":"39","author":"Alayli","year":"2005","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180314010236_key002-B134","first-page":"eS2","article-title":"The human and economic burden of g-to-treat gouty arthritis","volume":"82 (Suppl 1)","author":"Bardin","year":"2015","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B135","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B136","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","article-title":"Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases","volume":"15","author":"Ottaviani","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B137","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180314010236_key002-B138","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semarthrit.2015.02.006","article-title":"Anakinra for the treatment of acute severe gout in critically ill patients","volume":"45","author":"Thueringer","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B139","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","article-title":"Anakinra\u2019s efficacy is variable in refractory gout: report of ten cases","volume":"40","author":"Chen","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10067-014-2601-7","article-title":"Anakinra treatment in patients with gout and type 2 diabetes","volume":"34","author":"Vitale","year":"2015","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B141","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with g-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B142","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0196-0644(96)70238-X","article-title":"Clinical significance of reported changes in pain severity","volume":"27","author":"Todd","year":"1996","journal-title":"Ann Emerg Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B143","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B144","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B145","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B146","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B147","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2474-13-174","article-title":"Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout","volume":"13","author":"Dalbeth","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t20180314010236_key002-B148","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2013-203226","article-title":"Managing gout needs more than drugs: \u2018Il faut le savoir-faire, l\u2019Art et mani\u00e8re\u2019","volume":"72","author":"Liot\u00e9","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B149","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jbspin.2017.04.002","article-title":"GOSPEL 3: management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century \u2013 comparison with 2006 EULAR Recommendations","volume":"84","author":"Goossens","year":"2017","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B151","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2017.03.013","article-title":"Persistent clinical inertia in gout in 2014: an observational French longitudinal patient database study","author":"Maravic","year":"2017","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B152","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B153","first-page":"529","article-title":"Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B154","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","article-title":"Racial disparities in the risk of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States","volume":"46","author":"Lu","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B156","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180314010236_key002-B157","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B158","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B159","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180314010236_key002-B160","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B161","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B162","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B163","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B164","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0014-2999(93)90033-E","article-title":"Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees","volume":"250","author":"Komoriya","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20180314010236_key002-B165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B166","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B167","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B168","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout","volume":"161","author":"Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180314010236_key002-B169","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18553\/jmcp.2015.21.2.165","article-title":"Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective","volume":"21","author":"Gandhi","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"key\n\t\t\t\t20180314010236_key002-B170","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2016.09.020","article-title":"Efficacy and safety of febuxostat in 73 gouty patients with stage 4\/5 chronic kidney disease: a retrospective study of 10 centers","volume":"84","author":"Juge","year":"2017","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B171","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B172","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jbspin.2014.02.015","article-title":"Rational pharmacotherapy (RPT) in goutology: define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs","volume":"82","author":"Jansen","year":"2015","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180314010236_key002-B173","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B174","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.20634","article-title":"Mechanisms of benzarone and benzbromarone-induced hepatic toxicity","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B175","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","volume":"(11)","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180314010236_key002-B176","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit\u2013risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20180314010236_key002-B177","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B178","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B179","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180314010236_key002-B181","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B182","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2016-210767","article-title":"Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study","volume":"77","author":"Latourte","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B183","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.56.11.696a","article-title":"Serum uric acid in acute gout","volume":"56","author":"Logan","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B184","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","article-title":"Does starting allopurinol prolong acute treated gout? A randomized clinical trial","volume":"21","author":"Hill","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20180314010236_key002-B185","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","article-title":"Prophylaxis for acute gout flares after initiation of urate-lowering therapy","volume":"53","author":"Latourte","year":"2014","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B186","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180314010236_key002-B187","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B188","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180314010236_key002-B189","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.2010.1638","article-title":"Fructose-rich beverages and risk of gout in women","volume":"304","author":"Choi","year":"2010","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180314010236_key002-B190","doi-asserted-by":"crossref","first-page":"h3576","DOI":"10.1136\/bmj.h3576","article-title":"Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction","volume":"351","author":"Imamura","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180314010236_key002-B191","first-page":"31","article-title":"Sugar-sweetened beverages, urate, gout and genetic interaction","volume":"20","author":"Merriman","year":"2014","journal-title":"Pac Health Dialog"},{"key":"key\n\t\t\t\t20180314010236_key002-B192","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/ar4463","article-title":"Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge","volume":"16","author":"Dalbeth","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B193","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13075-015-0781-4","article-title":"Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout","volume":"17","author":"Dalbeth","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180314010236_key002-B194","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-015-0328-z","article-title":"Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE Trial","volume":"32","author":"Deedwania","year":"2015","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20180314010236_key002-B195","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","article-title":"Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"43","author":"Athyros","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180314010236_key002-B196","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/acr.22879","article-title":"You don\u2019t have to be a drinker to have gout, but it helps\u201d: a content analysis of the depiction of gout in popular newspapers","volume":"68","author":"Duyck","year":"2016","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/key002\/24340662\/key002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T01:03:11Z","timestamp":1520989391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article\/doi\/10.1093\/rheumatology\/key002\/4934129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":196,"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key002","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]}}}